{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T05:36:46Z","timestamp":1773725806829,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:00:00Z","timestamp":1663977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:00:00Z","timestamp":1663977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40120-022-00404-1","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T13:04:27Z","timestamp":1664024667000},"page":"1735-1748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6863-9340","authenticated-orcid":false,"given":"Lita","family":"Araujo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4497-3616","authenticated-orcid":false,"given":"Svend S.","family":"Geertsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen","family":"Amedume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janneke","family":"van Wingerden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,24]]},"reference":[{"key":"404_CR1","first-page":"175","volume":"37","author":"MM Goldberg","year":"2012","unstructured":"Goldberg MM. Multiple sclerosis review. PT. 2012;37:175\u201384.","journal-title":"PT"},{"key":"404_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18553\/jmcp.2012.18.S9-B.1","volume":"18","author":"DS Bandari","year":"2012","unstructured":"Bandari DS, Sternaman D, Chan T, Prostko CR, Sapir T. Evaluating risks, costs, and benefits of new and emerging therapies to optimize outcomes in multiple sclerosis. J Manag Care Pharm. 2012;18:1\u201317.","journal-title":"J Manag Care Pharm"},{"key":"404_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"Global Burden of Disease Study Group","year":"2019","unstructured":"Global Burden of Disease Study Group. Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:459\u201380.","journal-title":"Lancet Neurol"},{"key":"404_CR4","doi-asserted-by":"crossref","unstructured":"Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26:1816\u20131821.","DOI":"10.1177\/1352458520970841"},{"key":"404_CR5","first-page":"639","volume":"27","author":"NJ Engmann","year":"2021","unstructured":"Engmann NJ, Sheinson D, Bawa K, Ng CD, Pardo G. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in US commercial claims data. J Manag Care Spec Pharm. 2021;27:639\u201349.","journal-title":"J Manag Care Spec Pharm"},{"key":"404_CR6","first-page":"844","volume":"23","author":"KM Johnson","year":"2017","unstructured":"Johnson KM, Zhou H, Lin F, Ko JJ, Herrera V. Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year. J Manag Care Spec Pharm. 2017;23:844\u201352.","journal-title":"J Manag Care Spec Pharm"},{"key":"404_CR7","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.18553\/jmcp.2013.19.s1.S24","volume":"19","author":"J Menzin","year":"2013","unstructured":"Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm. 2013;19:S24-40.","journal-title":"J Manag Care Pharm"},{"key":"404_CR8","unstructured":"National Multiple Sclerosis Society. Disease-modifying therapies for MS. https:\/\/nms2cdn.azureedge.net\/cmssite\/nationalmssociety\/media\/msnationalfiles\/brochures\/brochure-the-ms-disease-modifying-medications.pdf. Accessed 22 Mar 2022."},{"key":"404_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102521","volume":"46","author":"P Vermersch","year":"2020","unstructured":"Vermersch P, Suchet L, Colamarino R, Laurendeau C, Detournay B. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014\u20132017. Mult Scler Relat Disord. 2020;46: 102521.","journal-title":"Mult Scler Relat Disord"},{"key":"404_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44\u20137.","journal-title":"Value Health"},{"key":"404_CR11","first-page":"629","volume":"5","author":"A Ri\u00f1on","year":"2011","unstructured":"Ri\u00f1on A, Buch M, Holley D, Verdun E. The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis. Patient Prefer Adherence. 2011;5:629\u201343.","journal-title":"Patient Prefer Adherence"},{"key":"404_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40120-021-00319-3","volume":"11","author":"G Pardo","year":"2022","unstructured":"Pardo G, Pineda ED, Ng CD, Bawa KK, Sheinson D, Bonine NG. Adherence to and persistence with disease-modifying therapies for multiple sclerosis over 24 months: a retrospective claims analysis. Neurol Ther. 2022;11:337\u201351.","journal-title":"Neurol Ther"},{"key":"404_CR13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2147\/CEOR.S130334","volume":"9","author":"J Burks","year":"2017","unstructured":"Burks J, Marshall TS, Ye X. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. Clinicoecon Outcomes Res. 2017;9:251\u201360.","journal-title":"Clinicoecon Outcomes Res"},{"key":"404_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10072-016-2806-4","volume":"38","author":"L Degli Esposti","year":"2017","unstructured":"Degli Esposti L, Piccinni C, Sangiorgi D, et al. Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs. Neurol Sci. 2017;38:589\u201394.","journal-title":"Neurol Sci"},{"key":"404_CR15","first-page":"205521731769611","volume":"3","author":"J Nicholas","year":"2017","unstructured":"Nicholas J, Ko JJ, Park Y, et al. Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing-remitting multiple sclerosis patients. Mult Scler J Exp Transl Clin. 2017;3:2055217317696114.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"404_CR16","doi-asserted-by":"publisher","first-page":"175628641989207","DOI":"10.1177\/1756286419892077","volume":"12","author":"M M\u00e4urer","year":"2019","unstructured":"M\u00e4urer M, Tiel-Wilck K, Oehm E, et al. Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord. 2019;12:1756286419892077.","journal-title":"Ther Adv Neurol Disord"},{"key":"404_CR17","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40801-021-00251-w","volume":"8","author":"L Freeman","year":"2021","unstructured":"Freeman L, Kee A, Tian M, Mehta R. Retrospective claims analysis of treatment patterns, relapse, utilization, and cost among patients with multiple sclerosis initiating second-line disease-modifying therapy. Drugs Real World Outcomes. 2021;8:497\u2013508.","journal-title":"Drugs Real World Outcomes"},{"key":"404_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1471-2377-13-138","volume":"13","author":"N Agashivala","year":"2013","unstructured":"Agashivala N, Wu N, Abouzaid S, et al. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol. 2013;13:138.","journal-title":"BMC Neurol"},{"key":"404_CR19","unstructured":"Garg N, McCarthy M, Karmarkar A. Oral therapies for MS. Pract Neurol. 2019;Nov\u2013Dec."},{"key":"404_CR20","first-page":"822","volume":"23","author":"AL Hincapie","year":"2017","unstructured":"Hincapie AL, Penm J, Burns CF. Factors associated with patient preferences for disease-modifying therapies in multiple sclerosis. J Manag Care Spec Pharm. 2017;23:822\u201330.","journal-title":"J Manag Care Spec Pharm"},{"key":"404_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.7224\/1537-2073.2013-053","volume":"17","author":"LS Wilson","year":"2015","unstructured":"Wilson LS, Loucks A, Gipson G, et al. Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis. Int J MS Care. 2015;17:74\u201382.","journal-title":"Int J MS Care"},{"key":"404_CR22","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/1756285616648060","volume":"9","author":"LD Lynd","year":"2016","unstructured":"Lynd LD, Traboulsee A, Marra CA, et al. Quantitative analysis of multiple sclerosis patients\u2019 preferences for drug treatment: a best-worst scaling study. Ther Adv Neurol Disord. 2016;9:287\u201396.","journal-title":"Ther Adv Neurol Disord"},{"key":"404_CR23","unstructured":"Genzyme Overview of Aubagio (teriflunomide) tablets, for oral use. https:\/\/products.sanofi.us\/Aubagio\/Aubagio.pdf. Accessed 22 Mar 2022."},{"key":"404_CR24","unstructured":"Biogen Tecfidera (dimethyl fumarate) delayed-release capsules, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204063lbl.pdf. Accessed 22 Mar 2022."},{"key":"404_CR25","unstructured":"Novartis US Gilenya (fingolimod) capsules. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022527s008lbl.pdf. Accessed 22 Mar 2022."},{"key":"404_CR26","unstructured":"Alkermes Vumerity (diroximel fumarate) delayed-release capsules, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211855s000lbl.pdf. Accessed 22 Mar 2022."},{"key":"404_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40263-020-00700-0","volume":"34","author":"RT Naismith","year":"2020","unstructured":"Naismith RT, Wundes A, Ziemssen T, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase\u00a0III EVOLVE-MS-2 study. CNS Drugs. 2020;34:185\u201396.","journal-title":"CNS Drugs"},{"key":"404_CR28","first-page":"1273","volume":"27","author":"J Mardan","year":"2021","unstructured":"Mardan J, Hussain MA, Allan M, Grech LB. Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression. J Manag Care Spec Pharm. 2021;27:1273\u201395.","journal-title":"J Manag Care Spec Pharm"},{"key":"404_CR29","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/ane.13301","volume":"142","author":"S Lahdenper\u00e4","year":"2020","unstructured":"Lahdenper\u00e4 S, Soilu-H\u00e4nninen M, Kuusisto HM, Atula S, Junnila J, Berglund A. Medication adherence\/persistence among patients with active multiple sclerosis in Finland. Acta Neurol Scand. 2020;142:605\u201312.","journal-title":"Acta Neurol Scand"},{"key":"404_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102566","volume":"46","author":"G Liang","year":"2020","unstructured":"Liang G, Chai J, Ng HS, Tremlett H. Safety of dimethyl fumarate for multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord. 2020;46: 102566.","journal-title":"Mult Scler Relat Disord"},{"key":"404_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40120-019-0127-2","volume":"8","author":"J Min","year":"2019","unstructured":"Min J, Cohan S, Alvarez E, et al. Real-world characterization of dimethyl fumarate-related gastrointestinal events in multiple sclerosis: management strategies to improve persistence on treatment and patient outcomes. Neurol Ther. 2019;8:109\u201319.","journal-title":"Neurol Ther"},{"key":"404_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.tips.2021.01.004","volume":"42","author":"A Hoogendoorn","year":"2021","unstructured":"Hoogendoorn A, Avery TD, Li J, Bursill C, Abell A, Grace PM. Emerging therapeutic applications for fumarates. Trends Pharmacol Sci. 2021;42:239\u201354.","journal-title":"Trends Pharmacol Sci"},{"key":"404_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/PPA.S24752","volume":"6","author":"CD Barbosa","year":"2012","unstructured":"Barbosa CD, Balp MM, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012;6:39\u201348.","journal-title":"Patient Prefer Adherence"},{"key":"404_CR34","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1177\/1756285616634247","volume":"9","author":"R Haase","year":"2016","unstructured":"Haase R, Kullmann JS, Ziemssen T. Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey. Ther Adv Neurol Disord. 2016;9:250\u201363.","journal-title":"Ther Adv Neurol Disord"},{"key":"404_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.msard.2017.07.006","volume":"17","author":"PK Coyle","year":"2017","unstructured":"Coyle PK, Khatri B, Edwards KR, et al. Patient-reported outcomes in relapsing forms of MS: real-world, global treatment experience with teriflunomide from the Teri-PRO study. Mult Scler Relat Disord. 2017;17:107\u201315.","journal-title":"Mult Scler Relat Disord"},{"key":"404_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102124","volume":"42","author":"F Patti","year":"2020","unstructured":"Patti F, Chisari CG, D\u2019Amico E, et al. Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study). Mult Scler Relat Disord. 2020;42: 102124.","journal-title":"Mult Scler Relat Disord"},{"key":"404_CR37","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1177\/1352458518790390","volume":"25","author":"F Sacc\u00e0","year":"2019","unstructured":"Sacc\u00e0 F, Lanzillo R, Signori A, et al. Determinants of therapy switch in multiple sclerosis treatment-na\u00efve patients: a real-life study. Mult Scler. 2019;25:1263\u201372.","journal-title":"Mult Scler"},{"key":"404_CR38","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3111\/13696998.2012.667027","volume":"15","author":"JI Ivanova","year":"2012","unstructured":"Ivanova JI, Bergman RE, Birnbaum HG, Phillips AL, Stewart M, Meletiche DM. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. J Med Econ. 2012;15:601\u20139.","journal-title":"J Med Econ"},{"key":"404_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12325-010-0093-7","volume":"28","author":"H Tan","year":"2011","unstructured":"Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther. 2011;28:51\u201361.","journal-title":"Adv Ther"},{"key":"404_CR40","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3111\/13696990903579501","volume":"13","author":"MW Reynolds","year":"2010","unstructured":"Reynolds MW, Stephen R, Seaman C, Rajagopalan K. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. J Med Econ. 2010;13:90\u20138.","journal-title":"J Med Econ"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00404-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00404-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00404-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T13:32:50Z","timestamp":1666445570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00404-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,24]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["404"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00404-1","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,24]]},"assertion":[{"value":"24 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}